On Invalid Date, Autolus Therapeutics (NASDAQ: AUTL) reported Q4 2023 earnings per share (EPS) of -$0.45, up 95.65% year over year. Total Autolus Therapeutics earnings for the quarter were -$77.17 million. In the same quarter last year, Autolus Therapeutics's earnings per share (EPS) was -$0.23.
As of Q2 2024, Autolus Therapeutics's earnings has grown year over year. Autolus Therapeutics's earnings in the past year totalled -$208.38 million.
What is AUTL's earnings date?
Autolus Therapeutics's earnings date is Invalid Date. Add AUTL to your watchlist to be reminded of AUTL's next earnings announcement.
What was AUTL's revenue last quarter?
On Invalid Date, Autolus Therapeutics (NASDAQ: AUTL) reported Q4 2023 revenue of $0.00 up 100% year over year. In the same quarter last year, Autolus Therapeutics's revenue was $3.83 million.
What was AUTL's revenue growth in the past year?
As of Q2 2024, Autolus Therapeutics's revenue has grown -73.3% year over year. This is 221.71 percentage points lower than the US Biotechnology industry revenue growth rate of 148.4%. Autolus Therapeutics's revenue in the past year totalled $1.70 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.